⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16819026 | 1.00 | — | — | |
| SCHEMBL16843469 | 1.00 | — | — | |
| SCHEMBL8232312 | 0.88 | MEN1 (0.37) | — | |
| SCHEMBL8155103 | 0.88 | MEN1 (0.33) | — | |
| SCHEMBL8154569 | 0.79 | MEN1 (0.34) | — | |
| SCHEMBL23670849 | 0.78 | — | — | |
| SCHEMBL23670846 | 0.78 | — | — | |
| SCHEMBL23670850 | 0.78 | — | — | |
| SCHEMBL8160982 | 0.76 | MEN1 (0.36) | — | |
| SCHEMBL23527362 | 0.76 | GBA1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111320610-A | Macrocyclic HCV NS3 inhibits the synthesis of tripeptides | 吉利德制药有限责任公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-105849118-B | Macrocyclic HCV NS3 inhibits the synthesis of tripeptides | 吉利德制药有限责任公司 | 2020-03-31 | — | — | CN | disclosed |
| EP-3087085-B1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3087086-B1 | CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9862728-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862728-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2017-09-21 | — | — | US | disclosed |
| WO-2015100145-A1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2015095430-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF MACROLACTAMS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |